Revolution Medicines (RVMD) net income: −$1.1B
Revolution Medicines reported a net loss of −$1.1B for the year ended Dec 31, 2025.
From Revolution Medicines's filings with the SEC · Read the filing · RVMD stock page
Revolution Medicines net income by year
#3,712 of 3,748 US companies by net income · See the full ranking
| Year ended | Net income | Change |
|---|---|---|
| Dec 31, 2025 | −$1.1B | – |
| Dec 31, 2024 | −$600M | – |
Net income of similar companies
Companies in the same industry as Revolution Medicines, by SEC industry code, with the closest net income. Each name opens the same page for that company.
| Company | Net income, latest year | Year ended |
|---|---|---|
| Vaxcyte | −$767K | Dec 31, 2025 |
| Twist Bioscience | −$130M | Sep 30, 2026 |
| Kodiak Sciences | −$230M | Dec 31, 2025 |
| Scholar Rock Holding | −$378M | Dec 31, 2025 |
| Immunovant | −$506M | Mar 31, 2026 |
| Revolution Medicines | −$1.1B | Dec 31, 2025 |
| Moderna | −$2.8B | Dec 31, 2025 |
Questions and answers
What is Revolution Medicines's net income?
Revolution Medicines reported a net loss of −$1.1B for the year ended Dec 31, 2025.
Numbers as reported in Revolution Medicines's annual and quarterly reports to the SEC (XBRL data). A year is the company's fiscal year that falls mostly in that calendar year; balances such as cash and debt are as of the date shown. Data only, not investment advice. Methodology